Geloren’s success lies in the high concentration of its active ingredient, Nutrihyl®. Nutrihyl® is hyaluronic acid specially developed for the joint nutrition of mammals. As a result, orally administered hyaluronic acid is as effective as possible when passing through the digestive tract.
Feed supplements containing Nutrihyl® help to prevent joint problems and are also effective in treating the early stages of joint disease. This active ingredient is completely safe and has no side effects.
Nutrihyl® reduces friction in the joints and absorbs shocks
The synovial fluid in joints plays the role of a lubricant and shock absorber; it transports important nutrients and removes waste products from the joint capsule. A key component of synovial fluid is hyaluronic acid. As soon as the level of this acid within the joint falls, joint-related difficulties and diseases emerge – mostly arthrosis, osteoarthritis, osteochondrosis, synovitis or tendinitis. Some common symptoms of joint diseases include pain, stiffness and reduced mobility of the joints and tendons.
Food enrichment with Geloren, the feed supplement containing Nutrihyl®, helps to prevent or significantly mitigate these difficulties.
Studies consistently demonstrate the efficacy of Nutrihyl®
- The peroral administration of Nutrihyl® significantly decreased the swelling of rat limbs caused by the development of adjuvant arthritis. A positive effect was detected even at low daily doses (0.1 mg/kg of body weight).
- At the university orthopaedic clinic in Prague, a study was conducted with 27 patients who had undergone knee surgery. The group used a mixture of Nutrihyl® and chondroitin sulphate for 90 days. Before and after the study, patients and physicians rated the swelling, pain and ability to move.
- At the Institute of Sports Medicine in Prague, 24 top-flight ice-hockey players took Nutrihyl® for 90 days during the season. The condition of the athletes’ knees was evaluated before and after treatment by a doctor. The efficacy of treatment was expressed by the following parameters: joint mobility, muscle strength, joint stability and intra-articular problems.
- The effect of the peroral administration of Nutrihyl® was investigated in a group of rats in which osteoporosis had been experimentally induced (a simulation of the process in post-menopausal women). In urine, Nutrihyl® significantly reduced the presence of substances indicating damaged bone tissue and optimised bone tissue density compared to a group of rats not given Nutrihyl®.
- The efficacy of Nutrihyl® was also explored at seven veterinary facilities, involving a total of 53 horses with various joint difficulties, e.g. with acute, subacute and chronic osteoarthritis, arthrosis, synovitis, tendovaginitis and osteochondrosis. The study saw a clear improvement in the joint problems of 91% of horses 30 days after completion of the study. The active ingredient inhibited inflammation in severely irritated joints, and its use resulted in reduced joint swelling, alleviated limping and pain relief.
The results of testing show that orally administered Nutrihyl® also activates the synthesis of nitric oxide, which has a positive effect on wound healing, hair growth and regenerative processes in the skin.
How Nutrihyl® is made?
Nutrihyl® has been developed and is made by Contipro, the exclusively Czech biotech company recognised as a world leader in the production of hyaluronic acid and its derivatives. Nutrihyl® is created by modifying the hyaluronic acid obtained through fermentation, i.e. by natural means. Raw Nutrihyl® is distinguished by high purity. It is not toxic and does not cause any allergic reactions.
Smedsrod, B., Pertoft, H., Eriksson, S., Fraser, J.R.E. and Laurent, T. Studies in vitro on the uptake and degradation of sodiumhyaluronate in rat liver endothelial cells, Biochem J. (1984), 223, 617-626
Nimrod, A., Ezra, E., Ezov, N., Nachum, G., and Parisada, B. Absorption, distribution, metabolism, and excretion of bacteria-derived hyaluronic acid in rats and rabbits, J. Ocul Pharmacol (1992), 8, 161-172
Reed, R.K., Townsley, M.I., Laurent, T.C., Taylor A.E. Hyaluronan flux from from cat intestine: changes with lymph flow, Am J. Physiol Heart Circ Physiol (1992), 262,H457-H462
Brown, T.J., Alcorn, D., Robert, J. and Fraser, E. Absorption of hyaluronan applied to the surface of intact skin, J. Invest Dermatol (1999) , 113, 740-746
Breborowicz, A., Polubinska, A., Pawlaczyk, K., Kuzlan-Pawlaczyk, M., Moberly, J., Martis, L. and Oreopoulos, D., Interperitoneal hyaluronan administration in concious rats: absorption, metabolism, and effects on peritoneal fluid dynamics, Peritoneal Dial Internat (2001), 21, 130-136
Schauss, A.G., Balogh, L.G., Polyak A.G., Mathe D.G., Kiraly R.G. and Janoki, G.G. Absorption, distribution and excretion of the 99mtechnetium labeled hyaluronan after single oral doses in rats and beagle dogs, Experimental biology (2004), Washington (2004)
Thierry, B., Winnik, F.M., Merhi, Y., Silver, J. And Tabrizian, M. Radionuclides-hyaluronan-conjugate thomboresistant coating to prevent in-stent restenosis, Biomaterials (2004), 25, 3895-3905
Stancikova, M., Svik, K., Istok, R. and Velebny, V. The effects of hyaluronan on bone resorption and bone mineral density in rat model of estrogen deficiency-induced osteopenia, Tissue reaction, International Journal of Tissue Reactions 22, 9-16 (2004)
Schwentker, A., Vodovotz, Y., Weller, R. And Billiar, T.R. Nitric oxide and wound repair: role of cytokines Nitric oxide (2002), 7, 1-10
Frank, S., Kaempfer, H., Wetzler, C., Pfeilchifter, J., Nitric oxide drives skin repair: Novel function of an established mediator, Kidney Internat (2002), 61, 882-888
Mochizuki, S., Vink, H., Hiramatsu, O., Kajita, T., Shigeto, F., Spaan, J.A.E. and Kajiya, F. Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release, Am J. Physiol Heart Circ Physiol (2003), 285, H722-H726